Consolidating ffelp loans into direct loans
Our advanced research, practice materials, and compliance tools provide the most accurate and wide-reaching research and guidance available to tax, accounting, and corporate finance professionals.
From our Income Tax Developments Wizard, to our Standards and Bill Trackers, or our vast assortment of Checkpoint Tools, we offer a tool to meet all of your needs.
Recent award-winning and innovative solutions include Checkpoint Catalyst™ (the fastest, most efficient way to perform complex tax research online) as well as Intuitive Search (the advanced online search technology that goes beyond keyword matching to truly understand what you are looking for) and deliver the best results, every time.
Now featuring EY Tax Alerts — timely updates and authoritative insights on key developments With the addition of EY Tax Alerts, Checkpoint delivers an unsurpassed selection of outstanding industry-specific news sources — such as PPC, WG&L, RIA and Reuters — to keep you current with important developments in the industry and legislative changes that may impact your clients.
[…] Retrospective on 2016 Tax Developments While the 2016 calendar year was relatively quiet on the legislative front, it brought many tax developments in the form of new regulations — some of which were extremely controversial.
[…] Four Ways to Avoid Audit and Attest Deficiencies Many avid hikers have learned the hard way that hiking on damp rocks can be dangerous.
We offer a variety of news products and services so you can access the legislative updates, primary source releases, pronouncements, general business and specific industry news, and of course, exclusive Reuters, World Trade Executive, Boskage and others — and you’ll see why Checkpoint delivers the most comprehensive research solutions available for federal tax, state and local tax, international tax, audit, accounting, finance, trade and employee benefits professionals.
1 Gallon (3,785 m L) SAFE-GUARD fenbendazole suspension Product Information Product Type OTC ANIMAL DRUG NDC Product Code (Source) 57926-088 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Fenbendazole (Fenbendazole) Fenbendazole 100 mg in 1 m L Inactive Ingredients Ingredient Name Strength methylparaben propylparaben silicon dioxide carboxymethylcellulose sodium povidone trisodium citrate dihydrate citric acid monohydrate water Product Characteristics Color Score Shape Size Flavor Imprint Code Contains Packaging # NDC Package Description Multilevel Packaging 1 57926-088-01 3785 m L In 1 BOTTLE None Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA128620 09/16/2009 Labeler - Schering Corporation (001317601) Establishment Name Address ID/FEI Operations Intervet Production S. 771867553 ANALYSIS, MANUFACTURE Revised: 09/2009Schering Corporation read more Class: Vitamin DATC Class: A11CCVA Class: VT509Chemical Name: (1? 110 111 113 117 Closely monitor serum calcium and phosphate concentrations during therapy.110 117 (See Patient Monitoring under Cautions.) Administration Oral Administration Administer orally once daily or 3 times weekly without regard to meals.117 If paricalcitol is administered 3 times weekly, administer no more frequently than every other day.117 IV Administration Administer by direct IV injection at (before, during, or after) dialysis, no more frequently than every other day.110 Dosage Pediatric Patients Secondary Hyperparathyroidism 500 pg/m L, initial dosage of 2 mcg once daily or 4 mcg 3 times weekly.117 Adjust dosage at 2- to 4-week intervals based on i PTH response.117 Maintain current dosage if decrease in i PTH concentration from baseline is ? 60%.117 If response is inadequate (i.e., i PTH concentration increases, remains unchanged, or is reduced by 5 CKD (Dialysis) IV Initial dosage of 0.04–0.1 mcg/kg (2.8–7 mcg) at dialysis (no more often than every other day).110 Adjust dosage at 2- to 4-week intervals with the goal of reducing i PTH concentration to no more than 1.5–3 times ULN.110 Maintain current dosage if decrease in i PTH concentration from baseline is ? 60% or if i PTH concentration is 1.5–3 times the ULN.110 If response is inadequate (i.e., i PTH concentration increases, remains unchanged, or is reduced by 75, reduce or withhold dosage immediately until parameters are normalized; reinitiate drug at a lower dosage. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third of labor and reduces blood loss. Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/m L observed at 1.12 ± 0.82 hours.… continue reading »
Sanaa Lathan, actress (Monica Wright): The script was great. How people identify with the movie, I identified with the script and their story.… continue reading »